Pharmacokinetics and Variation in the Clearance of Oxycodone and Hydrocotarnine in Patients with Cancer Pain
Open Access
- 1 January 2007
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 30 (11) , 2173-2177
Abstract
Compound injections of oxycodone and hydrocotarnine are currently used as one of the treatment options for some cases with cancer pain. However, there have been no reports examining the factors that influence oxycodone and hydrocotarnine clearance, so detailed examination is necessary. As for hydrocotarnine, there have been no reports examining the pharmacokinetics. Therefore in this study, we determined the pharmacokinetics of oxycodone and hydrocotarnine in patients with cancer pain. The study was conducted on 19 patients, in whom pain control was attempted by using the compound injections of oxycodone and hydrocotarnine. We used HPLC-electrochemical detector (ECD) to determine oxycodone and hydrocotarnine serum concentrations, and used the nonlinear least-squares method (MULTI) for calculation of the pharmacokinetic parameters. Furthermore, we examined the factors that influence the clearance of oxycodone and hydrocotarnine by multiple regression analysis (step wise method). The pharmacokinetic parameters were as follows: Oxycodone; Vd=226.7±105.5 l (mean±S.D.), CL=37.9±25.1 l/h, t1/2=4.1±1.9 h. Hydrocotarnine; Vd=276.8±237.2 l, CL=95.1±64.3 l/h, t1/2=2.0±0.7 h. The clearance of oxycodone represented by a regression formula was significantly correlated to the age, the presence or absence of within 7 d on the death or liver metastasis, or of the heart failure of the patients. The clearance of hydrocotarnine represented by a regression formula was significantly correlated to the presence or absence of within 7 d on the death or liver metastasis, or of the heart failure of the patients. The clearance also indicated that oxycodone concentration in the blood was likely to be higher in patients having these factors. Oxycodone/hydrocotarnine compound injections should be used with caution and dose reduction may be necessary in such populations.Keywords
This publication has 16 references indexed in Scilit:
- Determination of Oxycodone and Hydrocotarnine in Cancer Patient Serum by High-Performance Liquid Chromatography with Electrochemical DetectionAnalytical Sciences, 2005
- QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMESDrug Metabolism and Disposition, 2004
- Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patientsBritish Journal of Cancer, 2003
- Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinansLife Sciences, 1999
- Controlled‐release oxycodone compared with controlled‐release morphine in the treatment of cancer pain: A randomized, double‐blind, parallel‐group studyEuropean journal of pain, 1998
- Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient‐controlled analgesiaActa Anaesthesiologica Scandinavica, 1998
- The intrinsic antinociceptive effects of oxycodone appear to be κ -opioid receptor mediatedPain, 1997
- A nonlinear least squares program based on differential equations, MULTI (RUNGE), for microcomputers.Journal of Pharmacobio-Dynamics, 1983
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981
- Über PavinalOkayama Igakkai Zasshi (Journal of Okayama Medical Association), 1925